Indian startup Wellthy Therapeutics has secured additional financing, led by Beyond Next Ventures, a venture capital firm based in Japan, with participation from existing investors.

This paves the way for Wellthy Therapeutics to expand its platform into the Japanese market, enabling enterprise customers to deploy world class digital health solutions to support patients globally.

Wellthy Therapeutics' modular, low-code digital health platform is being used to build and deploy validated digital health solutions in multiple conditions. The company has previously announced the platform's FDA certification along with its existing EU MDR certification, which makes it South Asia's only chronic and multi-disease management platform to be certified for the same.

The platform has helped payor and life science enterprise customers in patient identification, therapy initiation and up-titration, boosting market share and driving adherence, while reducing the overall cost of care and medical claims and improving patient quality of life.

The startup is present across Europe and Asia and has impacted the outcomes for over 150,000 patients across these regions. It recently announced its expansion to the US, along with the platform's regulatory certifications for the same. With Beyond Next Ventures as a key shareholder, Wellthy Therapeutics is poised for further global growth and expansion in Japan. The company is already backed by financial investors such as Saama Capital, GrowX Ventures, Ranjan Pai's (Manipal) Family Office and Beenext Ventures.